Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vaqta (hepatitis A vaccine, legacy) by Year
Vaqta (hepatitis A vaccine, legacy) — International sales ($M) ($M)
Merck Vaqta (hepatitis A vaccine, legacy): $61M in FY2023, down 21.8% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-26) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaqta (hepatitis A vaccine, legacy) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 61 | -21.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 78 | -1.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 79 | +17.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 67 | -38.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 108 | -3.6% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 112 | -9.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 124 | – | Form 10-K (filed 2020-02-26) ↗ |
Cite this data
StockData. (2026). Merck Vaqta (hepatitis A vaccine, legacy) ($M), annual FY2017–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaqta-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.